Skip to content

13F-HR filed by JAY JEFFREY R

JAY JEFFREY R filed this 13F-HR for the quarter ended 2013-06-30, filed 2013-08-14, with 32 holding rows worth $126,545,000.

Accession
0000930413-13-004244
Filed
2013-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2013

A holdings report, 32 entries on the cover page, a total value of $126,545,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $126,545,000 with VALUE read as thousands by filing date, 13F file number 028-12517. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
HYPERION THERAPEUTICS INC44915N101COM963,961$21,207,000thousands by filing date
FURIEX PHARMACEUTICALS36106P101COM494,100$16,834,000thousands by filing date
STEMLINE THERAPEUTICS INC85858C107COM595,493$14,196,000thousands by filing date
BIODEL INC09064M204COM1,853,845$7,749,000thousands by filing date
AMBIT BIOSCIENCES CORP02318X100COM1,000,000$7,000,000thousands by filing date
GERON CORP374163103COM3,750,000$5,625,000thousands by filing date
PAIN THERAPEUTICS INC69562K100COM2,322,769$5,133,000thousands by filing date
SUNSHINE HEART INC86782u106COM950,000$5,101,000thousands by filing date
DURATA THERAPEUTICS INC26658A107COM639,433$4,604,000thousands by filing date
NORDION INC65563c105COM537,500$3,978,000thousands by filing date
HORIZON PHARMA INC44047T109COM1,596,720$3,928,000thousands by filing date
ONCOGENEX PHARMACEUTICALS IN68230A106COM347,004$3,401,000thousands by filing date
IMPAX LABORATORIES INC45256B101COM150,000$2,991,000thousands by filing dateput
TRINITY BIOTECH PLC896438306SPON ADR NEW163,140$2,749,000thousands by filing date
RTI BIOLOGICS INC74975N105COM673,898$2,534,000thousands by filing date
DYAX CORP26746E103COM728,063$2,519,000thousands by filing date
MAST THERAPEUTICS INC576314108COM5,800,000$2,490,000thousands by filing date
PROTALIX BIOTHERAPEUTICS INC74365A101COM399,007$1,959,000thousands by filing date
MYRIAD GENETICS INC62855J104COM70,000$1,881,000thousands by filing dateput
VOLCANO CORPORATION928645100COM100,000$1,813,000thousands by filing date
TARGACEPT INC87611R306COM367,709$1,570,000thousands by filing date
AVANIR PHARMACEUTICALS INC05348P401CL A NEW258,600$1,190,000thousands by filing datecall
XENOPORT INC98411C100COM232,977$1,153,000thousands by filing date
MEI PHARMA INC55279B202COM NEW157,661$1,124,000thousands by filing date
PERNIX THERAPEUTICS HOLDINGS71426V108COM297,187$1,073,000thousands by filing date
PALATIN TECHNOLOGIES INC696077403COM PAR $ .011,712,807$1,062,000thousands by filing date
VASCULAR SOLUTIONS INC92231M109COMMON STOCK46,200$680,000thousands by filing date
WRIGHT MED GROUP INC98235T115RIGHT 03/01/2019200,000$542,000thousands by filing date
CELSION CORPORATION15117N305COM NEW186,200$190,000thousands by filing date
ARTIVION INC228903100COM26,244$164,000thousands by filing date
GW PHARMACEUTICALS PLC36197T103ADS11,622$102,000thousands by filing date
AMAG PHARMACEUTICALS INC00163U106COM150$3,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000930413-13-004244this filing2013-08-14acceptance time not in the bulk data set